Signals
Signals
Signals: evidence-linked clusters of independent sources highlighting what’s changing now.
LiveWindow 24hEvidence trails in app
Signals dashboard
Sorted by impact x momentum. Use the chevron to expand a card. Use the action button for the full drawer.
No investment advice. Research signals and sources only. EarlyNarratives provides informational signals derived from public sources. It does not provide financial, legal, or tax advice.
Filters & sortTap to open
Filters
Sort by
Impact x momentum blends evidence strength with recent acceleration. See the whitepaper for methodology.
Filter matches title, tags, and tickers.
Limited evidence
Live dashboards and rankings are open; unlock source trails, evidence timestamps, archive access, workflow tools, and alerts.
New & accelerating
Fresh signals showing clear momentum shifts across sources.
New & accelerating
Preprints: AD plaque/cell proteomics, amyloid-PET subgrouping, and PET-tracked AAV deliver
Alzheimers disease (AD) arises from pathological interactions among diverse brain cell types, but cell-specific proteomic changes remain underexplored.
Updated 21h agoActive span 13h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.3
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
5
PostsCount of items included in the signal cluster for this window.Learn more
5
Details
1 publishers5 posts1 platformsTop source 100%
Evidence: 1 specialist
#1 of 6Structural
NewEmerging confirmationSingle source
preprintAlzheimer Disease
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Multiple neurodegeneration preprints posted within the same 24h window on bioRxiv.
- Convergent focus on measurement granularity: plaques, cell types, PET latent structure, and in vivo tracking.
- Cross-disease genetics angle: APOE ε4 examined beyond AD in an ALS cohort.
New & accelerating
Novo’s CagriSema tops semaglutide in Phase 3 diabetes; Pfizer’s monthly GLP-1 draws mixed
Coverage discusses speculative scenarios around ~$10B; treat as market chatter and see linked sources.
Updated 2d agoActive span 22h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.5
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
5
PostsCount of items included in the signal cluster for this window.Learn more
5
Details
3 publishers5 posts1 platformsTop source 40%
Evidence: 3 primary
#2 of 6Structural
NewBroad confirmationEmerging confirmation
Clinical TrialsMetabolic Disease
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
3
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
40%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Multiple outlets reported fresh trial readouts for CagriSema and Pfizer/Metsera within ~24 hours.
- Coverage emphasizes head-to-head comparisons (semaglutide/Ozempic; Zepbound) driving interpretation.
- Pfizer’s $10B Metsera acquisition puts added spotlight on early clinical validation signals.
New & accelerating
Trump funding bill ends partial shutdown and revives FDA pediatric voucher program
President Donald Trump signed a government funding bill that ended a partial shutdown and, according to coverage, reauthorized the FDA rare pediatric disease voucher program aimed at speeding development of drugs for rare childhood diseases.
Updated 28h agoActive span 3h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
3 publishers3 posts1 platformsTop source 33%
Evidence: 3 primary
#3 of 6Structural
NewBroad confirmationEmerging confirmation
fdaDrug Development Incentives
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
50%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
33%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- The provisions were enacted as part of a funding bill ending a partial shutdown
- Multiple outlets flagged the voucher program’s reauthorization in the same package
- Policy extensions (e.g., Medicare telehealth through 2027) create near-term planning signals
New & accelerating
FDA rejects AstraZeneca’s self-injected Saphnelo; FDA launches ‘PreCheck’ program
Multiple outlets report FDA rejected AstraZeneca’s application for a subcutaneous, self-administered version of lupus treatment Saphnelo delivered via a prefilled pen, which was positioned as an alternative to in-office infusions every four weeks.
Updated 2d agoActive span 2h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.3
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
3 publishers3 posts1 platformsTop source 33%
Evidence: 3 primary
#4 of 6Structural
NewBroad confirmationEmerging confirmation
fdaRegulatory Setback
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
3
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
33%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Three outlets reported the FDA decision and related regulatory updates within the same day.
- FDA’s “PreCheck” rollout was reported alongside multiple product-specific setbacks.
New & accelerating
Generate:Biomedicines, Flagship’s AI-driven antibody biotech, moves toward IPO
Generate:Biomedicines, an AI-driven, Flagship Pioneering-founded clinical-stage antibody biotech, is reported to be moving toward an IPO. Coverage notes the company’s substantial private fundraising and points to its work on a potential asthma therapy positioned as a competitor to Tezspire.
Updated 8h agoActive span 2h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.3
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
3 publishers3 posts1 platformsTop source 33%
Evidence: 3 primary
#5 of 6Structural
NewBroad confirmationEmerging confirmation
ipoBiotech Funding
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
3
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
33%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Company is reported to have filed for/pitched an IPO
- Multiple outlets are covering the move within the same news cycle
- IPO momentum is described as building for biotechs
New & accelerating
Preprints: synthesizable SMILES generation, phenotype-to-structure design, and GPCR–ligand
Three new preprints advance generative modeling for drug discovery workflows under practical constraints. S3-GFN proposes soft regularization and contrastive replay to bias a sequence-based GFlowNet toward synthesizable SMILES.
Updated 19h agoActive span 6h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.2
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
2 publishers3 posts1 platformsTop source 67%
Evidence: 2 specialist
#6 of 6Structural
NewEmerging confirmation
Drug DiscoveryComputational Biology
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
67%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Multiple related generative/flow-based preprints posted within ~24 hours.
- Methods emphasize practical constraints: synthesis, perturbation dynamics, compute.
- GPCRs and phenotypic datasets remain central in computational drug discovery.
Market chatter
Early chatter with momentum, still building evidence.
Market chatter
New preprints link antibody design models with MS de novo sequencing benchmarks
Two bioRxiv preprints released the same day address complementary parts of antibody development workflows.
Updated 26h agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
0.7
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts1 platformsTop source 100%
Evidence: 1 specialist
#1 of 5Chatter
NewLow evidenceSingle source
antibodiesDrug Discovery
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Both antibody-methods preprints were posted within the same 24-hour window
- Each targets a known workflow gap: design (generation/editing) vs measurement (sequencing/benchmarking)
- Both emphasize reusable infrastructure (pre-trained models and an online benchmarking platform)
Market chatter
Preprints outline PQC routes for missense variants and Golgi membrane proteins
Two bioRxiv preprints report new mechanistic insights into protein quality control (PQC).
Updated 8h agoActive span 12h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
0.7
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts1 platformsTop source 100%
Evidence: 1 specialist
#2 of 5Chatter
NewLow evidenceSingle source
rdpreprint
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Two related proteostasis preprints posted within the same 24h window
- New tools and screens (chemical biology; genome-wide CRISPR; VAMP-seq) expand PQC mapping
- Fresh mechanistic claims invite follow-up validation beyond preprint stage
Market chatter
New preprints push for more generalizable genomics AI and structured single-cell data
Two fresh arXiv preprints highlight reliability gaps and representation choices in genomics ML.
Updated 2d agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
0.7
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts1 platformsTop source 100%
Evidence: 1 specialist
#3 of 5Chatter
NewLow evidenceSingle source
genomicsComputational Biology
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Both preprints were newly posted to arXiv in the last day
- Seq2func and single-cell ML adoption increases attention to robustness and data design
- Data-centric and evaluation-focused approaches are gaining momentum in genomics AI
Market chatter
Preprints link T cell state to transcription-factor programs: overmaturation and NR4A-driv
A pair of bioRxiv preprints highlight transcription-factor programs as levers of T cell state. One reports that naive CD4 T cell aging follows a transcriptional trajectory resembling normal post-thymic maturation ("overmaturation") and links this to functional impact via TOX perturbation.
Updated 14h agoActive span 11h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
0.7
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts1 platformsTop source 100%
Evidence: 1 specialist
#4 of 5Chatter
NewLow evidenceSingle source
immunologyT Cells
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Both studies are newly posted preprints within the last day
- Methods include single-cell profiling and rapid, degron-based protein degradation
- Chronic stimulation/exhaustion and immune aging remain active R&D focus areas
Market chatter
Preprints: spatial surface-proteome mapping and oxygen-gradient assays for CAR-T function
Two bioRxiv preprints introduce spatially informed CAR-T evaluation methods.
Updated 2d agoActive span 5h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
0.7
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts1 platformsTop source 100%
Evidence: 1 specialist
#5 of 5Chatter
NewLow evidenceSingle source
rdpreprint
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Both studies were newly posted as bioRxiv preprints
- They target known CAR-T limitations: chronic stimulation effects and hypoxia-driven functional suppression
- Assay development is trending toward spatially explicit, high-content readouts
Signal
Preprints: functional genomics, PPGL transcriptomics platform, and AI mutation prediction
Three fresh preprints point to continued convergence of molecular profiling and computation in cancer research.
Updated 2d agoActive span 7h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.2
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
2 publishers3 posts1 platformsTop source 67%
Evidence: 2 specialist
#1 of 1Structural
NewEmerging confirmation
oncologyFunctional Genomics
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
67%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Multiple new preprints released within the last day across bioRxiv/medRxiv
- Growing emphasis on transcriptional subtypes, integrated datasets, and model-driven stratification
- Continued push toward practical tools (platforms, slide-based models) that can be used across centers